On December 20, 2017, Bristol Myers Squibb Company, Bavarian Nordic, and Enzo Biochem, Inc. filed an amicus brief in support of Amgen’s...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
BiosimilarsIP.com Legal provides analysis of legal decisions from federal courts and from the PTAB related to biologics and biosimilars.
-
-
On December 5, 2017, the Federal Circuit held oral argument in Momenta Pharmaceuticals, Inc. v. Bristol-Myers Squibb Company, 17-1694. The...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On December 14, 2017, the Federal Circuit issued an opinion in Amgen v. Sandoz, holding that the Biologics Price Competition and Innovation...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The FDA has only approved eight biosimilar products to date. The second most recently approved biosimilar is Mvasi (bevacizumab-awwb),...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
As we previously reported, Pfizer filed three IPR petitions against Biogen-owned patents claiming methods of treatment with rituximab in...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Several of the Federal Circuit’s initial decisions involving the Biologics Price Competition and Innovation Act (the “BPCIA”) focused...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On November 6, 2017, Sandoz, Inc. filed its eighth inter partes review (“IPR”) against AbbVie Biotechnology Ltd. (“AbbVie”),...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]